Verve was established with a mission to solve the global health epidemic of cardiovascular disease.
In 2018, Verve was founded by cardiology, gene editing and drug development pioneers seeking to find a solution for the global epidemic that is cardiovascular disease (CVD). Despite improvements to treatment and care over the last several decades, CVD remains the leading cause of death worldwide.
Disrupting the Chronic Care Model for Treating ASCVD
At Verve, we are striving to build the preeminent company developing gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of this condition that touches so many individuals worldwide, whether personally or through a loved one. Our goal is to disrupt the chronic care model for treating ASCVD by providing a new therapeutic approach with single-course gene editing medicines.
Creating the Future of Medicine
Since our founding in 2018, we have advanced multiple gene editing medicines from nonclinical studies to clinical development, launched first-in-human clinical trials for our PCSK9 and ANGPTL3 programs targeting cardiovascular disease and published proof-of-concept data for our PCSK9 base editors. Based on this data we believe that a single spelling change to DNA in the liver in humans can have a clinical effect, and that a new way to treat heart disease is possible.